At 17.7x earnings and just 13x forward earnings, DOCS trades like a no-growth healthcare utility despite posting a 24.50% operating margin and a 24.20% ROIC. A PEG of 1.4 suggests growth is not explosive, but it is reasonably priced relative to earnings expansion, particularly when paired with an Altman Z-Score of 15.3, which signals negligible bankruptcy risk. The balance sheet strength is reinforced by a 6.6 current ratio and manageable 37.40% debt-to-equity, indicating financial flexibility. The market is not pricing this like a distressed asset, but it is clearly not awarding it a premium multiple either—this looks like a stable compounder valued conservatively rather than a speculative growth name.